Latest Conference Coverage

NeurologyLive will be providing live coverage of AES 2019 from Baltimore beginning Saturday, December 7.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.

The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.

At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.

At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.

Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.

The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.

The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.

The clinical development of ND0612 includes 2 doses; a low dose for mid-stage Parkinson patients experiencing loss of motor control on oral therapy, and a high dose for severe disease in which oral drugs are no longer effective.

Acorda Therapeutics’ Inbrija, an inhalation powder formulation of levodopa, was associated with no significant increases in troublesome dyskinesia for patients being treated with carbidopa/levodopa.

Data of amantadine (Gocovri, Adamas) extended-release tablets suggested that the therapy is, in fact, safe and tolerable with a unique pharmacokinetic profile, and results in significant improvements in dyskinesia for patients with Parkinson disease.

Acadia Pharmaceuticals’ pimavanserin significantly improved Hamilton Depression Rating Scale scores for patients with Parkinson disease with depressive symptoms in an 8-week, open-label study.

Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.

The professor of medicine, neurology, at the University of Toronto shared insight into the importance of communication and a good network of physicians to an adult neurologist caring for patients with epilepsy.

The neurologist at the National MS Center and University Hospital, in Brussels, spoke to the decision-making process when treating women with MS who seek to get pregnant, or who are planning a family.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.

Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.

The GeNeuro agent showed marked reductions in brain atrophy in the thalamus and cerebral cortex through a long-term extension period treating patients with multiple sclerosis.